Human mutations in the Ca2+ sensor calmodulin (CaM) have been associated with CPVT susceptibility, suggesting that CaM dysfunction is a key driver of the disease. The gene discussed is CALM3; the disease is catecholaminergic polymorphic ventricular tachycardia.